{"id":"arotinolol-hydrochloride","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a combined alpha and beta-blocker, arotinolol inhibits both beta-1 and beta-2 adrenergic receptors as well as alpha-1 adrenergic receptors. This dual action reduces cardiac contractility and heart rate (beta effects) while also causing vasodilation (alpha effects), resulting in decreased blood pressure and reduced cardiac workload. It is used primarily in the treatment of hypertension and angina pectoris.","oneSentence":"Arotinolol hydrochloride is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate and blood pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:27:44.083Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT06780865","phase":"NA","title":"Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute of Hypertension","startDate":"2025-01-30","conditions":"Chronic Kidney Disease(CKD), Nocturnal Hypertension","enrollment":200},{"nctId":"NCT02612298","phase":"PHASE4","title":"Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2015-08","conditions":"Essential Hypertension","enrollment":198},{"nctId":"NCT01351636","phase":"PHASE4","title":"Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2011-04","conditions":"Chronic Kidney Disease","enrollment":300}],"_emaApprovals":[],"_faersSignals":[{"count":14,"reaction":"MALAISE"},{"count":13,"reaction":"PYREXIA"},{"count":12,"reaction":"FALL"},{"count":11,"reaction":"PNEUMONIA"},{"count":10,"reaction":"DECREASED APPETITE"},{"count":10,"reaction":"DIABETES MELLITUS"},{"count":9,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":9,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":9,"reaction":"HEPATIC FUNCTION ABNORMAL"},{"count":8,"reaction":"ANAEMIA"}],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Almarl"],"phase":"marketed","status":"active","brandName":"Arotinolol Hydrochloride","genericName":"Arotinolol Hydrochloride","companyName":"Sumitomo Pharma (Suzhou) Co., Ltd.","companyId":"sumitomo-pharma-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arotinolol hydrochloride is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate and blood pressure. Used for Hypertension, Angina pectoris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}